Wellness is a German policy fight today

Policy moves in Germany are redrawing access to care and treatment in real time, showing the pull-and-push of healthcare systems.

In today's read: 1. GLP-1s lead a new fat-loss R&D wave · 2. Longevity moves into medical school, consumer tech · 3. Germany rewrites healthcare access rules · 4. Nervous system signals are the new consumer gold

1. GLP-1s lead a new fat-loss R&D wave

Pharma is chasing novel pathways to reduce specific types of fat, not just general weight. This includes targeting visceral fat and using RNAi to silence fat-promoting receptors, indicating a move beyond GLP-1s alone.

Watch for combination therapies and highly targeted drugs to carve out new niches in the obesity market. This signals that general weight loss is old news; precise body composition change is the new frontier.

Evidence from today:

• Sironax reaches 50% enrollment in obesity drug trial with semaglutide — Longevity.Technology — Sironax hit 50% enrollment in its Phase 2 trial for SIR4156, an oral NAMPT activator, which they're testing alongside semaglutide for obesity. The study aims to see how this combo affects body composition and metabolic markers in adults.
• Roche bets $1.1B on RNAi drug for selective fat loss — Longevity Technology — Rona Therapeutics licensed its investigational RNAi drug, targeting ALK7, to Roche in a deal worth up to $1.1 billion. The drug aims to selectively reduce visceral and ectopic fat by silencing the ALK7 receptor, which is expressed in adipose tissue, while preserving lean mass.
• Caliway's new injection targets and shrinks visceral fat — Deutsches Ärzteblatt — Taiwanese pharma company Caliway Biopharmaceuticals is reporting new findings on a novel injectable compound. Delivered in multiple subcutaneous doses, the drug doesn't just reduce fat under the skin, but also specifically targets visceral fat around organs. This research, presented at a European congress, suggests a new way to tackle a type of fat strongly linked to metabolic dysfunction.

2. Longevity moves into medical school, consumer tech

The longevity conversation is shifting from niche biohacking to mainstream medical education and consumer product development. It’s also attracting serious money and intellectual capital to address age-related decline, not just diseases of aging.

Expect more devices and services to hit the market that claim to 'optimize' aging, not just treat symptoms. Medical schools integrating longevity could mean a pipeline of doctors ready to prescribe novel aging interventions, not just manage chronic conditions.

Evidence from today:

• Lovehoney launches MenoPulse device for menopause symptoms — Longevity Technology — Lovehoney Group, through its SheHerMe brand, released MenoPulse—a clitoral air-pulse device designed to ease menopause symptoms. This device uses targeted stimulation, with early data suggesting an impact on autonomic function. It's a new entry on the pharmacy shelf for women navigating menopause.
• Medical Schools Should Teach Biology of Aging as Core Subject — El Médico Interactivo — José Luis Cordeiro advocates for integrating the biology of aging into medical school curricula as a fundamental discipline. This shift would equip future doctors to treat aging itself as a medical condition, moving beyond just managing age-related diseases. The goal is to make longevity science a standard part of future medical practice.
• XPRIZE gives $1M to mitochondrial drug team Mighty Therapeutics — Longevity.Technology — Mighty Therapeutics and the University of Washington just landed $1 million from XPRIZE Healthspan for their work on the drug elamipretide. They'll use the pilot data to design a larger trial for older adults. The goal is to improve cellular energy production and combat age-related decline.

3. Germany rewrites healthcare access rules

German health policy is undergoing significant regulatory changes. This includes lowering screening ages, streamlining therapy access, and mandates for doctors, indicating a top-down effort to control and improve patient access, often against practitioner resistance.

This push-and-pull between state mandates and medical autonomy will continue. Watch for other European nations to either emulate Germany's moves for access or resist its centralizing tendencies. This redefines who holds power in healthcare delivery.

Evidence from today:

• Germany mandates doctor appointment reporting despite physician protests — Deutsches Ärzteblatt — Germany's Bundestag passed a reform bill requiring contracted doctors to report available appointment slots, overriding strong opposition from the German Medical Association. Physicians argue it weakens medical autonomy by tying scheduling to external mandates. This aims to improve patient access to care.
• German rule change simplifies access to psychotherapy — Deutsches Ärzteblatt — Germany's GBA has streamlined regulations for outpatient psychotherapy, reducing the need for initial doctor consultations that check for physical causes. The goal is to cut down bureaucracy, making it easier for people to start therapy sessions faster. This directly impacts how quickly someone can address their mental health without jumping through extra hoops.
• Germany Lowers Mammogram Screening Age to 45 for Public Insurance — Deutsches Ärzteblatt — Germany's Joint Federal Committee (GBA) unanimously approved lowering the eligibility age for public health insurance-covered mammography screenings to 45. Previously, coverage typically started at 50, but now women between 45 and 69 can access the screening every two years, impacting millions.

4. Nervous system signals are the new consumer gold

Brands are recognizing that influencing the nervous system—through scent, sound, touch, or even lifestyle—is a direct pathway to consumer perceived wellness. This moves beyond 'feeling good' to measurable biological and psychological shifts.

Expect more products to be marketed with claims of nervous system regulation, autonomic function improvement, or stress reduction, moving beyond vague 'mood' benefits. This is a battleground for who can prove a direct impact on the body's internal state.

Evidence from today:

• Bath & Body Works tests scents via Hype Lab for nervous system response — Modern Retail — Bath & Body Works is launching small-batch fragrances through its new 'Hype Lab' initiative. The goal is to quickly gauge consumer interest and identify scents that resonate with current cultural moments, directly influencing mood and emotional states through olfaction.
• Lovehoney launches MenoPulse device for menopause symptoms — Longevity Technology — Lovehoney Group, through its SheHerMe brand, released MenoPulse—a clitoral air-pulse device designed to ease menopause symptoms. This device uses targeted stimulation, with early data suggesting an impact on autonomic function. It's a new entry on the pharmacy shelf for women navigating menopause.
• Unfair Chores Raise Relationship Stress, Says New Study — Videnskab.dk (Health) — New research from the University of Queensland, published in Scientific Reports, links uneven distribution of household chores to increased cognitive, emotional, and physical strain in relationships. They argue these burdens are key to assessing relationship health, beyond just fairness. I read it as another data point for why chronic stress erodes everything.

Also moved today

• FCC fund cuts could increase kids' screen time, anxiety — Ars Technica - Science & Health — FCC cuts to school internet funding could unintentionally increase unsupervised screen time and digital wellness issues for kids.
• Reservoir launches immune cell banking for future health — Longevity Technology — Reservoir is now banking immune cells, pushing biological insurance as a new frontier in personalized longevity.
• Blood test reveals varying Alzheimer's drug response — Longevity Technology — A blood test shows Alzheimer's drug response is highly individual, meaning amyloid clearance doesn't always equal cognitive gain.
• Consumers Expect More From Gut Health Than Just Digestion — Vitafoods Insights — Consumers want more from gut health than just digestion; they expect benefits for mood and immunity, signaling an expanded market.
• Cutting UPFs eases depression symptoms in new study — Healio - Psychiatry & Mental Health — Cutting ultra-processed foods showed a reduction in depression symptoms, further linking diet directly to mental health outcomes.
• LASIK-type eye surgery safe for inactive eczema patients — Deutsches Ärzteblatt — New research confirms LASIK-type eye surgery is safe for patients with inactive eczema, expanding access to vision correction.
• German Doctors Warn Against Insurers Controlling Digital Health Appointments — Deutsches Ärzteblatt — German doctors are fighting health insurers over control of digital patient access, a battle for the digital front door of healthcare.
• Denmark and UK Diverge on Schizophrenia Care Post-Diagnosis — Videnskab.dk (Health) — Denmark and the UK have diverging strategies for schizophrenia care post-diagnosis, highlighting different philosophies on integrated support.

New this week in wellness goods

• Reservoir launches immune cell banking for future health — global — A new service from the Cellino team, called Reservoir, lets you bank your immune cells now for potential use in future therapies. The idea is to save your youngest, most robust immune cells today for later use in regenerative medicine. Think of it as a biological insurance policy for your future self.
• Lovehoney launches MenoPulse device for menopause symptoms — menopause — Lovehoney Group, through its SheHerMe brand, released MenoPulse—a clitoral air-pulse device designed to ease menopause symptoms. This device uses targeted stimulation, with early data suggesting an impact on autonomic function. It's a new entry on the pharmacy shelf for women navigating menopause.
• Bath & Body Works tests scents via Hype Lab for nervous system response — Bath & Body Works is launching small-batch fragrances through its new 'Hype Lab' initiative. The goal is to quickly gauge consumer interest and identify scents that resonate with current cultural moments, directly influencing mood and emotional states through olfaction.

Signal map

Europe: 21 · Global: 12 · North America: 10 · Nordics: 4 · Oceania: 3 · Africa: 1

What I'd watch next

Pay attention to how these German policy changes unfold; they're a test case for system-wide reform and medical autonomy. Also, keep an eye on how nervous system claims are substantiated in new consumer products. Everyone wants 'calm' now, but can they prove it?

Where this fits at Kokorology

These market dynamics aren't just theoretical. Understanding these shifts helps you design better solutions. My Nervous System Journal offers a structured way to observe your own nervous system responses to daily inputs, making sense of your unique biological blueprint.